**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Javier Torres, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru

**Main Body of the Abstract**
Background: Cardiac amyloidosis (CA) is a frequently underdiagnosed condition that carries a high fatality risk when left untreated or detected late.
Methods: We conducted an analysis of all patients diagnosed with CA at our institution between January 1st, 2021, and August 31st, 2023. Notably, specific therapy was unavailable for ATTR patients, whereas all AL amyloidosis patients received chemotherapy, while only one receiving immunotherapy. All-cause mortality was extracted from national census data and analyzed using Kaplan-Meier survival estimates and long-rank test. Due to the size of the sample, non-parametric statistical tests were applied.
Results: Nineteen patients were diagnosed with CA, with 13 (68.4%) presenting with amyloid light chain (AL) amyloidosis, and 6 (31.6%) with transthyretin amyloidosis (ATTR) (4 wild-type and 2 variant). The median age was 66 years, and 68% were male. The mean delay in diagnosis from initial medical consultation was 10.77 months, showing no statistically significant difference between AL amyloidosis and ATTR (p=0.598 Mann-Whitney test), nor did it correlate with heightened mortality rates. Throughout a mean follow-up of 9.81 months, the median survival time was 10.56 months, with AL amyloidosis patients exhibiting the shortest survival (p=0.001). Gender differences in mortality were not statistically significant (p=0.387), and neither were global longitudinal strain (p=0.128 Mann-Whitney test) nor left ventricular ejection fraction (p=0.189 Mann-Whitney test) at the time of diagnosis.
Conclusions: AL amyloidosis patients had significantly lower survival rates during a short follow-up period, highlighting the urgent need for improved early detection and tailored treatments for the underserved population in the region.



**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Javier Torres, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru

**Main Body of the Abstract**
**Background:** Cardiac amyloidosis (CA) is a frequently underdiagnosed condition that carries a high fatality risk when left untreated or detected late.
**Methods:** We conducted an analysis of all patients diagnosed with CA at our institution between January 1st, 2021, and August 31st, 2023. Notably, specific therapy was unavailable for ATTR patients, whereas all AL amyloidosis patients received chemotherapy, while only one receiving immunotherapy. All-cause mortality was extracted from national census data and analyzed using Kaplan-Meier survival estimates and long-rank test. Due to the size of the sample, non-parametric statistical tests were applied.
**Results:** Nineteen patients were diagnosed with CA, with 13 (68.4%) presenting with amyloid light chain (AL) amyloidosis, and 6 (31.6%) with transthyretin amyloidosis (ATTR) (4 wild-type and 2 variant). The median age was 66 years, and 68% were male. The mean delay in diagnosis from initial medical consultation was 10.77 months, showing no statistically significant difference between AL amyloidosis and ATTR (p=0.598 Mann-Whitney test), nor did it correlate with heightened mortality rates. Throughout a mean follow-up of 9.81 months, the median survival time was 10.56 months, with AL amyloidosis patients exhibiting the shortest survival (p=0.001). Gender differences in mortality were not statistically significant (p=0.387), and neither were global longitudinal strain (p=0.128 Mann-Whitney test) nor left ventricular ejection fraction (p=0.189 Mann-Whitney test) at the time of diagnosis.
**Conclusions:** AL amyloidosis patients had significantly lower survival rates during a short follow-up period, highlighting the urgent need for improved early detection and tailored treatments for the underserved population in the region.



Mortality patterns among patients with cardiac amyloidosis in a tertiary care center in Latin America PA120 (#332)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.